VEEV Expands IQVIA Partnership With Clinical Operations Software Suite

Impact · against what's priced in

The IQVIA partnership expansion is a positive catalyst for Veeva as it provides a scalable channel to counteract R&D segment maturity, which the market currently discounts. For IQVIA, the news is largely a confirmation of its existing operational strategy and is already reflected in its bullish valuation.

VEEV+0.20

Challenges what's priced in

The price assumes

A re-acceleration in the R&D segment that overcomes current product maturity headwinds